118th Congress (2023-2024) ed
Which Weight Loss Option May Fit Your Goals
So its entirely reasonable to ask how drugs that enhance insulin action such as GLP-1 medications like semaglutide or tirzepatide can reduce harmful visceral fat, lower the risk of heart attack and stroke, and possibly even influence long-term cancer risk
In NAFLD mice, liraglutide could improve the hypoadiponectinemia-induced inflammatory stress by inhibiting the MKK4/JNK signaling pathway, inhibit liver adipogenesis by activating AMPK, and induce autophagy through the AMPK/mTOR pathway, hence improving the levels of liver lipids (23, 198)
This blog draws from insights shared during our recent webinar on payer perspectives on GLP-1 therapies, using data from our 2025 Trends in Drug Benefit Design Report
Presented at American Diabetes Association 2026 Scientific Sessions, New Orleans